




Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1(currently amended): A compound having the formula (I):



or a pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 5-7 membered ring containing 1 or 2 nitrogen ring atoms or an aza bicyclo octane ring;

HetAr is a 5 or 6 membered heteroaromatic ring containing 1-3 nitrogen ring atoms, or isoxazolyl, thiazolyl, thiadiazolyl, quinoliny, quinazolinyl, purinyl, pteridinyl, benzimidazolyl, pyrrolopyrimidinyl, or imidazopyridinyl;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-;

A is -C[[0]] 1-4alkyl-;

B is aryl(CH₂)_{0.3}-O-C(O)-, heteroaryl(CH₂)_{1.3}-O-C(O)-, indanyl(CH₂)_{0.3}-O-C(O)-, aryl(CH₂)_{1.3}-C(O)-, aryl-cyclopropyl-C(O)-, heteroaryl-cyclopropyl-C(O)-, heteroaryl(CH₂)_{1.3}-C(O)-, aryl(CH₂)_{1.3}-, heteroaryl(CH₂)_{1.3}-, aryl(CH₂)_{1.3}-NH-C(O)-, aryl(CH₂)_{1.3}-NH-C(NCN)-, aryl(CH₂)_{1.3}-SO₂-, heteroaryl(CH₂)_{1.3}-SO₂-, wherein any of the

aryl or heteroaryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro; and

X is H, OH, F, C₁₋₄alkyl, C₁₋₄alkoxy, NH₂, or X taken with an adjacent bond is =O.

Claim 2(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is aryl(CH₂)₀₋₃-O-C(O)-, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 3(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 4(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

HetAr is an isoxazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 5(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

HetAr is a thiadiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 6(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

HetAr is a 5 membered heteroaromatic ring containing 2 nitrogen ring atoms;

Al
HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 7(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

HetAr is quinolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 8(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 9(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 10(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

A1
HetAr is thiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 11(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 12(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

HetAr is pyrrolopyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 13(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

HetAr is a imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 14(currently amended): The compound according to Claim 2, or a pharmaceutically acceptable salts thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 15(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is aryl(CH₂)₁₋₃-SO₂-, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 16(currently amended): The compound according to Claim 15, or a pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 17(currently amended): The compound according to Claim 15, or a pharmaceutically acceptable salts thereof, wherein

HetAr is quinazolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 18(currently amended): The compound according to Claim 15, or a pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 19(currently amended): The compound according to Claim 15, or a pharmaceutically acceptable salts thereof, wherein

HetAr is imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 20(currently amended): The compound according to Claim 15, or a pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-,

heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 21(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 5 membered ring containing 1 nitrogen ring atom; and

B is aryl(CH₂)₀₋₃-O-C(O)-, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 22(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 23(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is pteridinyll optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 24(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-,

heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 25(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 26(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is aryl(CH₂)₀₋₃-O-C(O)-, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 27(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 28(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-,

heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 29(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atom; and

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 30(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is aryl(CH₂)_{1,3}-SO₂-, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 31(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is heteroaryl(CH₂)_{1,3}-C(O)-, wherein the heteroaryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 32(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is aryl(CH₂)_{1,3}-C(O)-, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 33(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is aryl-cyclopropyl-C(O)-, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 34(currently amended): The compound according to Claim 33, or a pharmaceutically acceptable salts thereof, wherein

A HetAr is pyridyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 35(currently amended): The compound according to Claim 33, or a pharmaceutically acceptable salts thereof, wherein

HetAr is pyrazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 36(currently amended): The compound according to Claim 33, or a pharmaceutically acceptable salts thereof, wherein

HetAr is pyridazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 37(currently amended): The compound according to Claim 33, or a pharmaceutically acceptable salts thereof, wherein

HetAr is pyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 38(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and


B is heteroaryl(CH₂)₁₋₃-O-C(O)-, wherein the heteroaryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro;.

Claim 39(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salts thereof, wherein
















NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and


B is aryl(CH₂)₁₋₃-NH-C(NCN)-, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 40(original): The compound according to Claim 1, wherein said compound is


















41



















A1


Al

Al







or a pharmaceutically acceptable salt thereof.

Claim 41(original): The compound according to Claim 1, wherein said compound is


Al






or a pharmaceutically acceptable salt thereof.


Claim 42(withdrawn): The compound according to Claim 1, wherein said compound is



or a pharmaceutically acceptable salt thereof.


Claim 43(original): The compound according to Claim 1, wherein said compound is







or a pharmaceutically acceptable salt thereof.

Claim 44(currently amended): The compound according to Claim 1, wherein said compound is






Al




or a pharmaceutically acceptable salt thereof.

Claim 45(currently amended):
compound is


The compound according to Claim 1, wherein said



Al




AI



or a pharmaceutically acceptable salt thereof.


Claim 46(currently amended):
compound is

The compound according to Claim 1, wherein said



or a pharmaceutically acceptable salt thereof.

Claim 47(withdrawn): The compound according to Claim 1, wherein said compound is



or a pharmaceutically acceptable salt thereof.

Claim 48(original): A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to claim 1.

Claim 49(currently amended): ~~The A pharmaceutical composition according to claim 48 useful for the treatment of pain.~~ comprising an inert carrier and an amount of a compound according to claim 1 effective to treat pain.

Claim 50(currently amended): ~~The A pharmaceutical composition according to claim 48 useful for the treatment of~~ comprising an inert carrier and an amount of a compound according to claim 1 effective to treat migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke.

Claim 51(original): A method of treating pain comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.

A1

Claim 52(original): A method of treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.
